Specialty drugs meet all four of the criteria of the “Specialty Drug” rule (1 TAC Section 354.1853). The specialty drug list (SDL) identifies all drugs meeting these criteria. The SDL is published quarterly. More information about the criteria and when HHSC publishes the SDL is part of the Specialty Drug Drug Process (PDF).
Draft SDL for Comment
Each quarter HHSC reviews drugs meeting the rule criteria. This resulting list is published as the quarter’s draft SDL.
HHSC welcomes comments from all external stakeholders regarding the draft. Stakeholders propose additions to, or removals from, the draft using the Specialty Drug Submission Spreadsheet (XLS).
A final SDL, incorporating approved public comment, is published each quarter.